Skip to main content

Table 2 Demographic and clinical characteristics of the hypertensive patients aged ≥75 years in the clinical trial study

From: Assessing the effectiveness of statin therapy for alleviating cerebral small vessel disease progression in people ≥75 years of age

  Placebo group (n = 109) Rosuvastatin group (n = 118) P value
Clinical parameters
 Female (n [%]) 52 (47.7) 57 (48.3) 0.928
 Age (years) 78.48 ± 2.58 78.24 ± 2.35 0.465
 Current smoking (n [%]) 28 (25.7) 23 (19.5) 0.264
 Alcohol consumption (n [%]) 34 (31.2) 33 (28.0) 0.594
 Body mass index (kg/m2) 23.57 ± 2.21 23.94 ± 2.49 0.226
 Heart rate (bpm) 67.21 ± 6.41 67.51 ± 5.45 0.706
 SBP (mm Hg) 157.23 ± 9.50 156.80 ± 9.74 0.735
 DBP (mm Hg) 71.14 ± 7.21 70.76 ± 7.35 0.699
Biochemical parameters
 TCHO (mmol/L) 5.08 ± 0.66 5.12 ± 0.69 0.696
 TG (mmol/L) 1.51 ± 0.39 1.48 ± 0.39 0.625
 HDL-C (mmol/L) 1.12 ± 0.19 1.17 ± 0.19 0.061
 LDL-C (mmol/L) 3.28 ± 0.72 3.28 ± 0.75 0.989
 FPG (mmol/L) 5.70 ± 0.66 5.62 ± 0.67 0.333
Brain magnetic resonance imaging
 WMH (mL) 6.57 (5.16, 8.11) 6.93 (4.87, 8.03) 0.907
 WMH-to-ICV ratio (%) 0.54 (0.40, 0.69) 0.54 (0.40, 0.66) 0.871
 Prevalence of Fazekas scale ≥2 (n [%]) 27 (24.8) 21 (17.8) 0.199
 Prevalence of lacunes (n [%]) 16 (14.7) 13 (11.0) 0.409
 Prevalence of Virchow-Robin spaces (n [%]) 12 (11.0) 11 (9.3) 0.674
 Prevalence of microbleeds (n [%]) 13 (11.9) 9 (7.6) 0.274
  1. Data are expressed as mean ± standard deviation, median with interquartile range, or numbers with percentages. Abbreviation list: SBP indicates systolic blood pressure; DBP, diastolic blood pressure; TCHO, total cholesterol; TG, triglycerides; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; FPG, fasting plasma glucose; WMH, white matter hyperintensities; ICV, intracranial volume